دورية أكاديمية
أعرض في EDS

Soluble MIC-A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma.

التفاصيل البيبلوغرافية
العنوان: Soluble MIC-A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma.
المؤلفون: Vela-Ojeda J; Departamento de Morfología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico., Olivas-Bejarano AC; Departamento de Morfología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico., Montiel-Cervantes LA; Departamento de Morfología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico.; Departamento de Hematología, Unidad de Investigación de Medicina Traslacional en Enfermedades Hemato Oncológicas, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad, Mexico City, Mexico., Rosales-Cruz E; Departamento de Morfología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico., Garcia-Gutierrez S; Departamento de Patología, Unidad Médica de Alta Especialidad, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Seris y Zaachila S/N Colonia La Raza, Mexico City, Mexico., Lezama-Palacios RA; Departamento de Morfología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico., Reyes-Maldonado E; Departamento de Morfología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico.
المصدر: European journal of haematology [Eur J Haematol] 2024 Sep; Vol. 113 (3), pp. 321-329. Date of Electronic Publication: 2024 May 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005->: Oxford : Blackwell
Original Publication: Copenhagen : Munksgaard, c1987-
مواضيع طبية MeSH: Lymphoma, Large B-Cell, Diffuse*/mortality , Lymphoma, Large B-Cell, Diffuse*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/diagnosis , Lymphoma, Large B-Cell, Diffuse*/blood , Germinal Center*/pathology , Germinal Center*/metabolism, Humans ; Female ; Male ; Middle Aged ; Aged ; Prognosis ; Adult ; Lymphocyte Subsets/metabolism ; Lymphocyte Subsets/immunology ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Treatment Outcome ; Neoplasm Staging ; Immunophenotyping ; Biomarkers, Tumor
مستخلص: Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma. MIC-A and MIC-B are the natural ligands for NKG2D, a receptor expressed in NK cells. MIC-A soluble isoforms (sMICA) have been described in different malignancies.
Objectives: To analyze lymphocyte subsets and sMIC-A in germinal center DLBCL.
Materials and Methods: sMICA, sMICB, and peripheral blood lymphocyte subsets (CD4+, CD8+, NK, NKT, γδ T cells, and dendritic cells) were analyzed in 59 patients and 60 healthy donors.
Results: Patients had decreased numbers of type 1 and type 2 dendritic cells, NK, iNKT, CD4 T, and CD8 T cells, and higher levels of sMIC-A. The 2-year PFS for high IPI scores and high sMIC-A was 24% and 28%, respectively. The 2-year OS for high IPI scores and high sMIC-A was 42% and 33%. The 2-year PFS and OS for patients not achieving response to treatment were 0% and 10%, respectively. The MICPI score (one point each for high IPI score and high sMIC-A) showed that those patients summing two points had worse PSF and OS.
Conclusions: Patients with DLBCL have decreased numbers of peripheral lymphocyte subsets and high levels of sMIC-A. The addition of sMIC-A to IPI could improve its prognostic relevance.
(© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
References: Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non‐hodgkin's lymphoma. Med Sci. 2021;9:5. doi:10.3390/MEDSCI9010005.
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443‐459. doi:10.3322/caac.21357.
Laurini JA, Anamarija MP, Boilesen E, Diebold J, MacLennan KA, et al. Classification of non‐Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood. 2012;120(24):4795‐4801. doi:10.1182/blood‐2012‐07‐440073.
de Moraes T, Hungria V, Chiattone C, Pavlovsky M, et al. Epidemiology of hematologic malignancies in real‐world settings: findings from the HematoOncology Latin America observational registry study. J Glob Oncol. 2019;5:1‐19. doi:10.1200/JGO.19.00025.
International Non‐Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non‐Hodgkin's lymphoma. N Engl J Med. 1993;329:987‐994. doi:10.1056/NEJM199309303291402.
Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R‐IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B‐cell lymphoma treated with R‐CHOP. Blood. 2007;109:1857‐1861. doi:10.1182/blood‐2006‐08‐038257.
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN‐IPI) for patients with diffuse large B‐cell lymphoma treated in the rituximab era. Blood. 2014;123:837‐842. doi:10.1182/blood‐2013‐09‐524108.
Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013;132:536‐544. doi:10.1016/j.jaci.2013.07.006.
Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 2015;3:575‐582. doi:10.1158/2326‐6066.CIR‐15‐0098.
Schmiedel D, Mandelboim O. NKG2D ligands–critical targets for cancer immune escape and therapy. Front Immunol. 2018;9:9. doi:10.3389/fimmu.2018.02040.
Xing S, Ferrari de Andrade L. NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cells. Clin Transl Immunol. 2020;9:e1230. doi:10.1002/cti2.1230.
Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 2020;8:17. doi:10.3389/fcell.2020.00017.
Feng X, Menga M, Lia H, et al. T‐cell dysfunction in natural killer/T‐cell lymphoma. Oncoimmunol. 2023;12(1):2212532. doi:10.1080/2162402X.2023.2212532.
Ray‐Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383‐5391. doi:10.1158/0008‐5472.CAN‐08‐3845.
Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4+ T‐cell immune response to large B‐cell non‐Hodgkin's lymphoma predicts patients outcome. J Clin Oncol. 2001;19(3):720‐726. doi:10.1200/JCO.2001.19.3.720.
Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245‐273. doi:10.1146/annurev.immunol.18.1.245.
Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B‐cell lymphomas correlate with prognosis. Clin Cancer Res. 2007;13(22):6666‐6672. doi:10.1158/1078‐0432.CCR‐07‐0504.
Chang‐Tsu Y, Shih‐Sung C, Pei‐Yuan C, et al. Decreased CD11c‐positive dendritic cells in the tumor microenvironment predict double‐hit/triple‐hit genotype and survival in diffuse large B‐cell lymphoma. J Pathol Clin Res. 2022;8:436‐447. doi:10.1002/cjp2.283.
Galati D, Zanotta S, Corazzelli G, et al. Circulating dendritic cell deficiencies as a new biomarker in classical Hodgkin lymphoma. Br J Haematol. 2019;184:594‐604. doi:10.1111/bjh.15676.
Dubois S, Waldmann TA, Müller JR. Effective cytotoxicity of dendritic cells against established T cell lymphomas in mice. J Immunol. 2021;207:1194‐1199. doi:10.4049/jimmunol.2001123.
Escriba‐Garcia L, Alvarez‐Fernandez C, Tellez‐Gabriel M, Sierra J, Briones J. Dendritic cells combined with tumor cells and alpha‐galactosylceramide induce a potent, therapeutic, and NK‐cell dependent antitumor immunity in B cells lymphoma. J Transl Med. 2017;15:115. doi:10.1186/s12967‐017‐1219‐3.
Klanova M, Oestergaard MZ, Trneny M, et al. Prognostic impact of natural killer cell count in follicular lymphoma and diffuse large B‐cell lymphoma patients treated with immunochemotherapy. Clin Cancer Res. 2019;25(15):4634‐4643. doi:10.1158/1078‐0432.CCR‐18‐3270.
Lin Z, Ma J, Ma Y, et al. Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma. Front Immunol. 2023;14:1191033. doi:10.3389/fimmu.2023.1191033.
Xu C, Vries R, Visser L, et al. Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. Am J Hematol. 2010;85(7):539‐541. doi:10.1002/ajh.21743.
Vela‐Ojeda J, Perez‐Retiguin FC, Olivas‐Bejarano AC, Garcia‐Ruiz Esparza MA, Garcia‐Chavez J, et al. Clinical relevance of NKT cells and soluble MIC‐A in Hodgkin lymphoma. Leuk Lymphoma. 2021;62(4):801‐809. doi:10.1080/10428194.2020.1852473.
Hayakawa Y, Kelly JM, Westwood JA, et al. Cutting edge: tumor rejection mediated by NKG2D receptor‐ligand interaction is dependent upon perforin. J Immunol. 2002;169:5377‐5381. doi:10.4049/jimmunol.169.10.5377.
Chitadze G, Lettau M, Bhat J, et al. Shedding of endogenous MHC class I‐related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer. 2013;133:1557‐1566. doi:10.1002/ijc.28174.
Belting L, Homberg N, Przewoznik M, Brenner C, Riedel T, et al. Critical role of the NKG2D receptor for NK cell‐mediated control and immune escape of B‐cell lymphoma. Eur J Immunol. 2015;45:2593‐2601. doi:10.1002/eji.201445375.
Yoon SE, Park S, Cho J, et al. The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B‐cell lymphoma. Front Oncol. 2023;13:1194315. doi:10.3389/fonc.2023.1194315.
Gupta M, Han JJ, Stenson M, et al. Elevated serum IL‐10 levels in diffuse large B‐cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. 2012;119:2844‐2853. doi:10.1182/blood‐2011‐10‐388538.
Giachelia M, Voso MT, Tisi MC, et al. Interleukin‐6 plasma levels are modulated by a polymorphism in the NF‐kappaB1 gene and are associated with outcome following rituximab‐combined chemotherapy in diffuse large B‐cell non‐Hodgkin lymphoma. Leuk Lymphoma. 2012;53:411‐416. doi:10.3109/10428194.2011.621566.
Spasevska I, Sharma A, Steen CB, et al. Diversity of intratumoral regulatory T cells in B‐cell non‐Hodgkin lymphoma. Blood Adv. 2023;7(23):7216‐7230. doi:10.1182/bloodadvances.2023010158.
Zhou S, Xu L, Ma Y, et al. Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B‐cell lymphoma. Oncotarget. 2017;8(12):19556‐19565. doi:10.18632/oncotarget.14700.
Mulder TA, Andersson ML, Peña‐Perez L, et al. Immune biomarkers in the peripheral blood and tumor microenvironment of classical Hodgkin lymphoma patients in relation to tumor burden and response to treatment. Hemasphere. 2022;6(11):e794. doi:10.1097/HS9.0000000000000794.
Korin L, Custidiano MR, Fuente ML, Cranco S, Vitriu A, et al. Percentage of infiltrating T lymphocytes in diffuse large B‐cell lymphoma lymph nodes measured by flow cytometry predicts overall survival and provides additional prognostic information when combined with the R‐IPI. Blood. 2019;134(suppl 1):1625. doi:10.1182/blood‐2019‐126193.
Roussel M, Le KS, Granier C, Llamas Gutierrez F, Foucher E, et al. Functional characterization of PD1+TIM3+ tumor‐infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Adv. 2021;5(7):1816‐1829. doi:10.1182/bloodadvances.2020003080.
معلومات مُعتمدة: SIP 2021 0994 Instituto Politecnico Nacional; SIP 2022 0999 Instituto Politecnico Nacional
فهرسة مساهمة: Keywords: IPI; T cells; diffuse large B‐cell lymphoma; sMIC‐A
المشرفين على المادة: 0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20240514 Date Completed: 20240802 Latest Revision: 20240802
رمز التحديث: 20240802
DOI: 10.1111/ejh.14230
PMID: 38742655
قاعدة البيانات: MEDLINE
الوصف
تدمد:1600-0609
DOI:10.1111/ejh.14230